Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | VNN1 | O95497 | 11/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CBX7 | O95931 | 1/20 | 0.39 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.39 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9583175 | 0.81 | NPC1 (0.41) | ALDH1A1 | |
| SCHEMBL28059870 | 0.81 | CTNNB1 (0.46) | HPGD | |
| SCHEMBL15512384 | 0.80 | CES2 (0.45) | ALDH1A1HPGD | |
| SCHEMBL6314039 | 0.80 | ERCC5 (0.47) | ALDH1A1HPGD | |
| SCHEMBL1712501 | 0.78 | NPC1 (0.45) | GSK3BALDH1A1HPGD | |
| SCHEMBL21820029 | 0.77 | S1PR3 (0.40) | ALDH1A1 | |
| SCHEMBL7644456 | 0.75 | GSK3B (0.59) | GSK3BVNN1GRM5ALDH1A1HPGD | |
| SCHEMBL29556203 | 0.74 | GSK3B (0.70) | GSK3BVNN1GRM5ALDH1A1 | |
| SCHEMBL2310105 | 0.74 | GSK3B (0.70) | GSK3BVNN1GRM5ALDH1A1 | |
| SCHEMBL481291 | 0.73 | MRGPRX4 (0.45) | GRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | GSK3B 1014/4885VNN1 4585/4885GRM5 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.